技術(shù)文章您現(xiàn)在的位置：首頁(yè) > 技術(shù)文章 > RecombiMAb anti-mouse CTLA-4 (CD152)（9D9-CP006單克隆抗體）介紹

RecombiMAb anti-mouse CTLA-4 (CD152)（9D9-CP006單克隆抗體）介紹

更新時(shí)間：2024-09-13 點(diǎn)擊次數(shù)：805次

9D9-CP006單克隆抗體是原始9D9單克隆抗體的重組嵌合型抗體?？勺兘Y(jié)構(gòu)域序列與原始9D9克隆號(hào)相同，但是恒定區(qū)序列已經(jīng)從小鼠IgG2b變?yōu)樾∈驣gG1。9D9-CP006單克隆抗體能與小鼠CTLA-4(細(xì)胞毒性T淋巴細(xì)胞抗原-4)反應(yīng)，CTLA-4也稱為CD152。CTLA-4是一種33 kDa的細(xì)胞表面受體，由屬于免疫球蛋白超家族CD28家族的Ctla4基因編碼。CTLA-4在活化的T淋巴細(xì)胞和B淋巴細(xì)胞上表達(dá)。CTLA-4在結(jié)構(gòu)上類似于T細(xì)胞共刺激蛋白CD28，兩種分子都與B7家族成員B7-1 (CD80)和B7-2 (CD86)結(jié)合。在與配體結(jié)合時(shí)，CTLA-4負(fù)調(diào)節(jié)細(xì)胞介導(dǎo)的免疫反應(yīng)。CTLA-4在誘導(dǎo)和/或維持免疫耐受、胸腺細(xì)胞發(fā)育和保護(hù)性免疫調(diào)節(jié)中起作用。CTLA-4在免疫下調(diào)中的關(guān)鍵作用已經(jīng)在CTLA-4缺陷小鼠中得到證實(shí)，這些小鼠在3-5周齡時(shí)由于淋巴增生性疾病的發(fā)展而死亡。CTLA-4是目前腫瘤免疫檢查點(diǎn)治療的熱門(mén)靶點(diǎn)之一。

產(chǎn)品詳情：

產(chǎn)品名稱	RecombiMAb anti-mouse CTLA-4 (CD152)
產(chǎn)品貨號(hào)	CP006
產(chǎn)品規(guī)格	1mg
反應(yīng)種屬	Mouse
克隆號(hào)	9D9-CP006
同種型	Mouse IgG1(switched from mouse IgG2b)
免疫原	Not available or unknown
實(shí)驗(yàn)應(yīng)用	in vivo CTLA-4 neutralization* Western blot* *Reported for the original mouse IgG2b 9D9 antibody
產(chǎn)品形式	PBS, pH 7.0,Contains no stabilizers or preservatives
純度	>95%, Determined by SDS-PAGE
聚合	<5%, Determined by SEC
無(wú)菌處理	0.2 µm filtration
純化方式	Protein G
分子量	150 kDa
小鼠病原檢測(cè)	Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative
保存條件	抗體原液保存在4°C，不能冷凍保存。
推薦同型對(duì)照	InVivoPlus mouse IgG1 isotype control, unknown specificity（貨號(hào)BP0083）
推薦抗體稀釋液	InVivoPure pH 7.0 Dilution Buffer（貨號(hào)IP0070）

該產(chǎn)品自上市已被多篇SCI文獻(xiàn)引用，品質(zhì)有保證，以下是部分已發(fā)表的文獻(xiàn)引用：

應(yīng)用

文章

體內(nèi)CTLA-4中和

(in vivo CTLA-4

neutralization)

1. Dai, M., et al. (2015). 'Curing mice with large tumors by locally delivering

combinations of immunomodulatory antibodies' Clin Cancer Res 21(5): 1127-1138.

2. Zippelius, A., et al. (2015). 'Induced PD-L1 expression mediates acquired

resistance to agonistic anti-CD40 treatment' Cancer Immunol Res 3(3): 236-244.

3. Redmond, W. L., et al. (2014). 'Combined targeting of costimulatory (OX40)

and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of

driving robust antitumor immunity' Cancer Immunol Res 2(2): 142-153.

4. Condamine, T., et al. (2014). 'ER stress regulates myeloid-derived suppressor

cell fate through TRAIL-R-mediated apoptosis' J Clin Invest 124(6): 2626-2639.

5. Muller, P., et al. (2014). 'Microtubule-depolymerizing agents used in antibody-drug

conjugates induce antitumor immunity by stimulation of dendritic cells' Cancer Immunol

Res 2(8): 741-755.

6. Bulliard, Y., et al. (2013). 'Activating Fc gamma receptors contribute to the antitumor

activities of immunoregulatory receptor-targeting antibodies' J Exp Med 210(9): 1685-1693.

BioXCell熱銷(xiāo)產(chǎn)品--RecombiMAb anti-mouse CTLA-4 (CD152)

更多產(chǎn)品詳情請(qǐng)聯(lián)系 BioXCell 中國(guó)授權(quán)代理——欣博盛生物

上一篇：Bioxcell InVivoPlus anti-mouse CD8α，抗小鼠CD8α抗體

下一篇：RecombiMAb anti-mouse PD-1 (CD279)（29F.1A12™-CP004單克隆抗體）介紹

返回列表>>